Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients

• Published in: British journal of haematology Vol. 128; no. 3; pp. 386 - 388
• Main Authors: Kennedy, Margaret, Andreescu, Astrid C. M., Greenblatt, Marc S., Jiang, Hongyu, Thomas, Christian A., Chassereau, Laurie, Wong, Cheung, Durda, Peter, Cushman, Mary
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.02.2005; Blackwell
• Subjects: Aged; Biological and medical sciences; Blood and lymphatic vessels; cancer; Cardiology. Vascular system; Case-Control Studies; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Factor V - genetics; factor V Leiden; Female; Genetic Predisposition to Disease; Hematologic and hematopoietic diseases; Hematology; Humans; Male; Medical sciences; Middle Aged; Neoplasms - complications; Neoplasms - genetics; Polymorphism, Genetic; Prothrombin - genetics; prothrombin 20210A; risk factor; Risk Factors; venous thrombosis; Venous Thrombosis - etiology; Venous Thrombosis - genetics; Human; Factor V Leiden; Hematology; Vein thrombosis; Cardiovascular disease; Malignant tumor; Epidemiology; Venous disease; Vascular disease; Thrombophilia; prothrombin 20210A; Risk factor; Prothrombin; Venous thrombosis; cancer
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1111/j.1365-2141.2004.05327.x

Summary Cancer patients have an increased risk of venous thrombosis (VT). The association of factor V Leiden (FVL) and the prothrombin 20210A variant with VT in cancer patients is not established. We genotyped 101 cancer patients with VT and 101 cancer patients without VT for these polymorphisms. Five cases and three controls were heterozygous for FVL, yielding an odds ratio of 1·7 (95% confidence interval (CI) 0·3–10·7). Five cases and no controls were heterozygous for prothrombin 20210A, for an odds ratio of 6·7 (95% CI 0·9–infinity). Prothrombin 20210A may be associated with VT risk among cancer patients.